Ibuprofen lysinate, quicker and less variable: relative bioavailability compared to ibuprofen base in a pediatric suspension dosage form


Por: Ferrero-Cafiero, JM, Gich, I, Puntes, M, Martinez, J, Ballester, MR, Coimbra, J, Mathison, Y, Tarre, M, Font, X, Antonijoan, RM

Publicada: 1 nov 2015
Resumen:
Objectives: To assess and compare the bioavailability of ibuprofen enantiomers (R and S) of two different pediatric suspensions: the first one with ibuprofen lysinate (Algidrin (R) Pediatric, FARDI S.A., Barcelona, Spain) and the second one with ibuprofen base (Daisy (R), Abbott Laboratories S.A., Madrid, Spain). Methods: A randomized, open-label, single-dose, balanced, crossover study under fasting conditions was performed at the CIM-Sant Pau. 24 healthy volunteers received a single dose of ibuprofen lysinate (Algidrin (R) Pediatric, FARDI S.A.) and ibuprofen base (Daisy (R), Abbott Laboratories S.A.) equivalent to 400 mg of ibuprofen. 18 blood samples were drawn, and ibuprofen enantiomer plasma concentrations were determined using an enantioselective analytical method. An analysis of variance (ANOVA) model was used, and the 90% confidence intervals (CI) were calculated; further analyses were made regarding rate of absorption and variability. Results: The pharmacokinetic parameters (Algidrin (R) Pediatrico vs. Daisy (R) (Mean +/- SD)) were: S-enantiomer: C-max = 22.39 +/- 5.33 vs. 19.97 +/- 3.19 mu g/mL; AUC(0)(t) = 74.83 +/- 16.69 vs. 74.64 +/- 14.80 mu gxh/mL, and AUC(0)(infinity) = 77.46 +/- 19.33 vs. 76.98 +/- 17.13 mu gxh/mL; and for R-enantiomer: C-max = 21.74 +/- 3.76 vs. 15.20 +/- 2.03 mu g/mL; AUC(0)(t) = 57.55 +/- 10.17 vs. 46.13 +/- 9.61 mu gxh/mL, and AUC(0)(infinity) value was 58.49 +/- 10.57 vs. 47.03 +/- 10.02 mu gxh/mL. The t(max) (Median) for S-enantiomer (active) were: 0.5 vs. 1.33 hours (p = 0.001) and for R-enantiomer: 0.5 vs. 1.0 hours (p = 0.004). Ibuprofen pharmacokinetic values may vary under fed state and in pediatric population. Conclusions: While 5-ibuprofen shows a similar bioavailability for AUC(0)(t), AUC(0)(infinity), and C-max, R-ibuprofen shows supra-bioavailability for the lysinate formulation. The rate of absorption of the ibuprofen lysinate suspension is quicker and less variable than that of the ibuprofen base reference suspension and it exhibits a shorter t(max), which is of particular interest for achieving a rapid and homogeneous analgesic and antipyretic effect.

Filiaciones:
Ferrero-Cafiero, JM:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Farmacol Clin, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain

Gich, I:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Farmacol Clin, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain

Puntes, M:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Farmacol Clin, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain

Martinez, J:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Farmacol Clin, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain

Ballester, MR:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Farmacol Clin, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain

Coimbra, J:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Farmacol Clin, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain

Mathison, Y:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

Tarre, M:
 SA FARDI, Lab Aplicac Farmacodinam, Barcelona, Spain

Font, X:
 SA FARDI, Lab Aplicac Farmacodinam, Barcelona, Spain

Antonijoan, RM:
 Inst Recerca Hosp Santa Creu & Sant Pau CIM St Pa, Ctr Invest Med, Barcelona 08025, Spain

 Univ Autonoma Barcelona, Hosp Santa Creu & St Pau, Farmacol Clin, Dept Farmacol & Terapeut, E-08193 Barcelona, Spain
ISSN: 09461965





INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
Editorial
DUSTRI-VERLAG DR KARL FEISTLE, BAHNHOFSTRASSE 9 POSTFACH 49, D-82032 DEISENHOFEN-MUENCHEN, GERMANY, Alemania
Tipo de documento: Article
Volumen: 53 Número: 11
Páginas: 972-979
WOS Id: 000365460200009
ID de PubMed: 26249766

MÉTRICAS